RO
ROIV.US Roivant Sciences Ltd
- Market cap
- USD 28.0B
- P/E
- -
- P/B
- 7.12x
- ROE
- -19.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is ROIV.US undervalued?
Graham numberThe Graham number of Roivant Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Roivant Sciences Ltd fundamental analysis
No fundamental analysis for Roivant Sciences Ltd yet.
Roivant Sciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizab…
Full company profileRoivant Sciences Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Roivant Sciences Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 2.32M | 67.7M | 23.8M | 55.3M | 31.5M | 32.7M | 29.1M | 8.26M | 73.1M |
| Gross Profit | 1.72M | 66.6M | 21.7M | 46.3M | 28.5M | 31.1M | 28.1M | 6.98M | 65.9M |
| Operating Income | -748M | -532M | -1.07B | -1.21B | -907M | 4.50B | -1.00B | -515M | -1.27B |
| EBITDA | 138M | -553M | -896M | -911M | -838M | 4.62B | -668M | -261M | -919M |
| Net Income | -1.04B | 1.20B | -809M | -845M | -1.01B | 4.35B | -172M | -300M | -763M |
| EPS | -4.84 | 1.75 | -1.18 | -1.26 | -1.42 | 5.23 | -0.24 | -0.43 | -1.06 |
| Balance Sheet | |||||||||
| Total Assets | 1.39B | 2.48B | 2.69B | 2.59B | 2.39B | 7.22B | 5.44B | 5.71B | 4.98B |
| Total Liabilities | 451M | 368M | 528M | 524M | 782M | 774M | 250M | 416M | 380M |
| Shareholders' Equity | 937M | 2.03B | 1.90B | 1.66B | 1.16B | 5.97B | 4.69B | 4.53B | 4.02B |
| Cash & Short-term Investments | 850M | 2.19B | 2.13B | 2.06B | 1.68B | 6.54B | 4.89B | 4.29B | 4.21B |
| Total Debt | 143M | 181M | 245M | 284M | 481M | 500M | 100M | 107M | 107M |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.02B | -762M | -552M | -678M | -843M | -765M | -839M | -750M | 648M |
| Capital Expenditure | 11.4M | 4.92M | 5.81M | 17.4M | 12.7M | 1.38M | 4.60M | 8.21M | 1.25M |
| Free Cash Flow | -1.04B | -767M | -558M | -695M | -856M | -767M | -844M | -759M | 647M |
| Ratios | |||||||||
| ROE | -111.2% | 59.1% | -42.6% | -51.0% | -87.2% | 72.9% | -3.7% | -6.6% | -19.0% |
| ROA | -75.1% | 48.5% | -30.1% | -32.7% | -42.2% | 60.2% | -3.2% | -5.3% | -15.3% |
| Net Profit Margin | -44,835.2% | 1,773.6% | -3,400.9% | -1,528.9% | -3,200.2% | 13,294.2% | -592.0% | -3,629.2% | -1,043.3% |
| Debt to Equity | 0.15x | 0.09x | 0.13x | 0.17x | 0.42x | 0.08x | 0.02x | 0.02x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Roivant Sciences Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | USD 6.00M | 0.01 | 0.1% |
| 2023 | USD 163M | 0.23 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Roivant Sciences Ltd
- Insiders 21.23%
- Institutions 78.77%
- Public & others 0.00%
- Shares outstanding 725M
- Free float 573M
Top funds holding ROIV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 23.0M | 3.18% | +0.15% | Aug 2026 |
| iShares Core S&P Mid-Cap ETF | 19.5M | 2.69% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 16.0M | 2.22% | +0.12% | Sep 2026 |
| Vanguard Small Cap Index | 11.4M | 1.57% | -1.76% | Sep 2026 |
| Invesco S&P MidCap Momentum ETF | 6.95M | 0.96% | -0.06% | Oct 2026 |
| Fidelity Growth Company K6 | 6.67M | 0.92% | +0.15% | Aug 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 6.33M | 0.88% | -4.75% | Sep 2026 |
| Fidelity Series Growth Company | 5.60M | 0.77% | +1.70% | Aug 2026 |
| Morgan Stanley Inst Growth I | 5.28M | 0.73% | -3.26% | Jun 2026 |
| iShares Biotechnology ETF | 4.08M | 0.56% | -0.32% | Oct 2026 |
| JPMorgan Large Cap Growth I | 4.07M | 0.56% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 4.01M | 0.55% | +21.48% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.79M | 0.52% | +2.68% | Oct 2026 |
| MS INVF US Advantage I | 3.63M | 0.50% | -7.01% | Sep 2026 |
| Fidelity Contrafund | 3.16M | 0.44% | -2.62% | Sep 2026 |
| MS INVF US Growth I | 3.02M | 0.42% | -5.99% | Sep 2026 |
| Vanguard Explorer Inv | 2.97M | 0.41% | -6.83% | Sep 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 2.95M | 0.41% | 0.00% | Oct 2026 |
| Pictet-Biotech P USD | 2.57M | 0.35% | +0.79% | Oct 2026 |
| Fidelity Extended Market Index | 2.48M | 0.34% | +13.04% | Sep 2026 |
Top institutions holding ROIV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 81.0M | 11.20% | +3.90% | Jun 2026 |
| BlackRock Inc | 48.2M | 6.67% | +9.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 42.6M | 5.89% | -17.82% | Jun 2026 |
| Qvt Financial LP | 23.7M | 3.28% | -5.72% | Jun 2026 |
| Vanguard Capital Management, LLC | 22.1M | 3.06% | +6.98% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 21.6M | 2.99% | +9.09% | Jun 2026 |
| The Goldman Sachs Group Inc | 18.6M | 2.56% | +67.00% | Jun 2026 |
| State Street Corp | 17.8M | 2.46% | +9.94% | Jun 2026 |
| UBS Group AG | 17.5M | 2.41% | -22.78% | Jun 2026 |
| Assenagon Asset Management SA | 16.7M | 2.31% | +136.36% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 14.3M | 1.98% | +47.90% | Jun 2026 |
| Geode Capital Management, LLC | 11.7M | 1.61% | +14.65% | Jun 2026 |
| Adage Capital Partners Gp LLC | 10.3M | 1.43% | -19.11% | Jun 2026 |
| Perceptive Advisors LLC | 8.09M | 1.12% | -2.41% | Jun 2026 |
| Patient Square Capital LP | 7.71M | 1.07% | -3.86% | Sep 2026 |
| Amvescap Plc. | 7.53M | 1.04% | +16.96% | Jun 2026 |
| Darwin Global Management, Ltd. | 6.75M | 0.93% | -0.74% | Jun 2026 |
| AQR Capital Management LLC | 6.63M | 0.92% | +11.55% | Jun 2026 |
| Viking Global Investors LP | 6.27M | 0.87% | -5.73% | Jun 2026 |
| Rubric Capital Management LP | 6.00M | 0.83% | +20.00% | Jun 2026 |
Roivant Sciences Ltd company profile
- Company name
- Roivant Sciences Ltd
- Ticker
- ROIV.US
- ISIN
- BMG762791017
- Exchange
- USA Stocks
- Listed since
- Oct 1, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 721
- Fiscal year end
- March
- Address
- 50 Broadway, London, United Kingdom, SW1H 0DB
- Phone
- 44 20 7400 3347
- Website
- roivant.com
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd management
10- Mr. Matthew GlineCEO & Director · born 1984
- Dr. Eric Venker M.D., Pharm.D.President & CEO of Immunovant · born 1987
- Dr. Mayukh Sukhatme M.D.President, Chief Investment Officer & Director · born 1976
- Dr. Frank M. Torti M.B.A., M.D.President & Vant Chair · born 1979
- Mr. Richard PulikChief Financial Officer · born 1980
- Ms. Jennifer HumesChief Accounting Officer · born 1981
- Mr. Ian RosenblumChief Information Officer
- Mr. Sam KaplanGeneral Counsel
- Ms. Kelly GraffHead of People
- Mr. Alex GasnerExecutive Vice President of Roivant Health